PMEL and melanoma: It is based on the ImmTAC (immune mobilizing monoclonal T cell receptors against cancer) platform (2) and targets the melanoma-associated antigen gp100 through a soluble TCR fused to an anti-CD3 T cell mobilizing domain (3).